For instance, lung cancer cells with EGFR mutations that have metastasized to the brain can develop resistance to Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), through the acquisition of an additional K-Ras G12V mutation [86]. The gene discussed is KRAS; the disease is lung cancer.